Table 4. Characteristics of the... | American Society of Hematology

Table 4.

Characteristics of the prospective cohort (n = 692)

	All patients, %	Less intensive, %	Intensive, %
Age, y
18-49	22	5	95
50-59	21	8	92
60-64	14	10	90
65-69	19	21	79
70-74	14	42	58
75-79	9	71	29
≥80	1	83	17
Augmented HCT-CI
0-1	15	14	86
2-3	29	17	83
4-5	23	21	79
≥6	33	24	76
2017 ELN cytogenetic risk
Favorable	21	12	88
Intermediate	43	17	83
Adverse	36	31	69
KPS
>70	83	16	84
≤70	17	45	55
AML-CM
0-3	13	6	94
4-6	32	15	85
7-9	32	25	75
≥10	23	32	68
Diagnosis
Newly diagnosed AML	77	18	82
Relapsed/refractory AML	14	21	79
High-risk MDS	9	44	56
Status posttreatment
Never achieved CR	44	34	66
Achieved CR	56	11	89

	All patients, %	Less intensive, %	Intensive, %
Age, y
18-49	22	5	95
50-59	21	8	92
60-64	14	10	90
65-69	19	21	79
70-74	14	42	58
75-79	9	71	29
≥80	1	83	17
Augmented HCT-CI
0-1	15	14	86
2-3	29	17	83
4-5	23	21	79
≥6	33	24	76
2017 ELN cytogenetic risk
Favorable	21	12	88
Intermediate	43	17	83
Adverse	36	31	69
KPS
>70	83	16	84
≤70	17	45	55
AML-CM
0-3	13	6	94
4-6	32	15	85
7-9	32	25	75
≥10	23	32	68
Diagnosis
Newly diagnosed AML	77	18	82
Relapsed/refractory AML	14	21	79
High-risk MDS	9	44	56
Status posttreatment
Never achieved CR	44	34	66
Achieved CR	56	11	89

CR, complete remission; MDS, myelodysplastic syndrome.